GlassScriptPhysician profile
Rose A Lasher
NPI 1093460073
$1,380.58
in general payments reported to CMS, 2019-2025
12 companies · $729 in 2025
The $729 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $203 · 2024: $449 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.59 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $302.40 | 2024-2025 | Erleada |
| Teleflex LLC | $240.37 | 2024-2025 | Urolift, Barrigel |
| Sumitomo Pharma America, INC. | $225.30 | 2023-2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $157.88 | 2024-2025 | Aquabeam System |
| Axonics, INC. | $147.59 | 2023-2024 | Bulkamid, Axonics |
| Novartis Pharmaceuticals Corporation | $91.22 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.65 | 2025 | |
| Medtronic, INC. | $39.03 | 2023-2024 | Interstim |
| Endo USA, INC. | $28.07 | 2025 | Xiaflex |
| Endo Pharmaceuticals INC. | $24.99 | 2023 | Xiaflex |
| Urogen Pharma, INC. | $19.88 | 2025 | |
| Angiodynamics, INC. | $18.20 | 2025 | Nanoknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Lasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.